- Home
- BRY vs NKTR Comparison
BRY vs NKTR Comparison
Compare BRY & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- NKTR
- Stock Information
- Founded
- BRY 1909
- NKTR 1990
- Country
- BRY United States
- NKTR United States
- Employees
- BRY N/A
- NKTR N/A
- Industry
- BRY Oil & Gas Production
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- BRY Energy
- NKTR Health Care
- Exchange
- BRY Nasdaq
- NKTR Nasdaq
- Market Cap
- BRY 186.1M
- NKTR 160.4M
- IPO Year
- BRY N/A
- NKTR 1994
- Fundamental
- Price
- BRY $2.40
- NKTR $0.64
- Analyst Decision
- BRY Hold
- NKTR Strong Buy
- Analyst Count
- BRY 1
- NKTR 6
- Target Price
- BRY $5.00
- NKTR $4.92
- AVG Volume (30 Days)
- BRY 1.2M
- NKTR 2.8M
- Earning Date
- BRY 05-08-2025
- NKTR 05-08-2025
- Dividend Yield
- BRY 14.99%
- NKTR N/A
- EPS Growth
- BRY N/A
- NKTR N/A
- EPS
- BRY 0.25
- NKTR N/A
- Revenue
- BRY $783,841,000.00
- NKTR $98,427,000.00
- Revenue This Year
- BRY N/A
- NKTR N/A
- Revenue Next Year
- BRY $2.60
- NKTR N/A
- P/E Ratio
- BRY $9.60
- NKTR N/A
- Revenue Growth
- BRY N/A
- NKTR 9.21
- 52 Week Low
- BRY $2.11
- NKTR $0.43
- 52 Week High
- BRY $8.88
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- BRY 35.10
- NKTR 45.85
- Support Level
- BRY $2.20
- NKTR $0.43
- Resistance Level
- BRY $2.37
- NKTR $0.68
- Average True Range (ATR)
- BRY 0.22
- NKTR 0.08
- MACD
- BRY -0.00
- NKTR 0.01
- Stochastic Oscillator
- BRY 24.58
- NKTR 72.41
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.